首页 › 基金 › Stonepine Capital Management, LLC › ACET
Stonepine Capital Management, LLC 对 ACET 的持仓历史
ADICET BIO INC · 医疗保健
Stonepine Capital Management, LLC 在 Q3 2026 的 13F 申报中披露持有 ACET(ADICET BIO INC)188,201 股,市值约 US$1.3M,约占其申报组合的 1.03%,在其申报持仓中市值排名第 24 位。 Stonepine Capital Management, LLC 最近 11 个申报季度中有 9 个季度披露了 ACET 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Stonepine Capital Management, LLC 对 ACET 的持仓演变
Stonepine Capital Management, LLC 于 Q1 2024 首次披露 ACET 持仓:141,548 股(约 US$333K)。 该持仓在 Q2 2026 达到峰值 245,518 股,市值约 US$2.1M。 在 9 次申报中,Stonepine Capital Management, LLC 4 次增持、2 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 188,201 股、市值约 US$1.3M,环比减持 -57,317 股。。 持仓曾出现大幅变动:Q2 2024 增持约 331% (随后一个季度股价上涨 19%)、Q1 2025 减持约 27% (随后一个季度股价下跌 19%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 141.55K | $332.64K | 新进 |
| Q2 2024 | 609.45K | $737.43K | 增持 |
| Q3 2024 | 609.45K | $877.60K | 持有 |
| Q4 2024 | 700.00K | $673.40K | 增持 |
| Q1 2025 | 508.27K | $203.50K | 减持 |
| Q4 2025 | 220.01K | $1.85M | 新进 |
| Q1 2026 | 221.96K | $1.51M | 增持 |
| Q2 2026 | 245.52K | $2.12M | 增持 |
| Q3 2026 | 188.20K | $1.34M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ACET 与 13F 数据
ACET(ADICET BIO INC)属于医疗保健行业。我们追踪的基金中还有 24 只申报持有 ACET,申报仓位最大的包括:Carlyle Group Inc. (US$1.3M), REGENERON PHARMACEUTICALS, INC. (US$432K)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ACET 的基金
- Carlyle Group Inc. 184.29K 股 · $1.32M · Q3 2026
- REGENERON PHARMACEUTICALS, INC. 60.51K 股 · $432.05K · Q3 2026
更多关于 Stonepine Capital Management, LLC
常见问题
How long has Stonepine Capital Management, LLC held ACET?
Stonepine Capital Management, LLC has disclosed ACET holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is Stonepine Capital Management, LLC's current position in ACET?
As of Q3 2026, Stonepine Capital Management, LLC holds 188.20K shares of ACET (ADICET BIO INC), valued at $1.34M, representing 1.03% of its reported portfolio and ranking #24.
Has Stonepine Capital Management, LLC been buying or selling ACET?
In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC reduced its position in ACET. The position peaked in Q2 2026 at 245.52K shares.
Which other funds hold ACET?
Other major institutional holders of ACET include Carlyle Group Inc., REGENERON PHARMACEUTICALS, INC., among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.